

THE LANCET

Infectious Diseases

Supplementary appendix

This appendix formed part of the original submission. We post it as supplied by the authors.

This online publication has been corrected. The corrected version first appeared at thelancet.com/infection on April 28, 2022.

Supplement to: Parker EPK, Desai S, Marti M, et al. Emerging evidence on heterologous COVID-19 vaccine schedules—To mix or not to mix? *Lancet Infect Dis* 2022; published online March 9. [https://doi.org/10.1016/S1473-3099\(22\)00178-5](https://doi.org/10.1016/S1473-3099(22)00178-5).

Appendix

The material below is adapted with permission from the WHO's *Interim recommendations for heterologous COVID-19 vaccine schedules* (published under a [CC BY-NC-SA 3.0 IGO](#) license).¹

Review methods

Search strategy for review of COVID-19 vaccine response following heterologous primary or boosting schedules

A search in MEDLINE was performed to identify articles published between 1 July 2020 and 19 November 2021 using the search terms listed below.

Row	Term	Purpose
1	Coronavirus/ or Coronaviridae/ or SARS-CoV-2/ or coronaviridae infections/ or coronavirus infections/ or covid-19/	Controlled MEDLINE vocabulary terms for COVID-19
2	("covid*" or "COVID-19*" or COVID19* or "COVID-2019*" or "COVID2019*" or "SARS-CoV-2*" or "SARSCoV-2*" or "SARSCoV2*" or "SARS-CoV2*" or "SARSCov19*" or "SARS-Cov19*" or "SARSCov-19*" or "SARS-Cov-19*" or "SARSCov2019*" or "SARS-Cov2019*" or "SARSCov-2019*" or "SARS-Cov-2019*" or SARS2* or "SARS-2*" or "SARScoronavirus2*" or "SARS-coronavirus-2*" or "SARScoronavirus 2*" or "SARS coronavirus2*" or "SARScoronavirus2*" or "SARS-coronavirus-2*" or "SARScoronavirus 2*" or "SARS coronavirus2*" or (coronavirus* or coronavirus* or coronavirinae* or CoV) or ((corona* or corono*) adj1 (virus* or viral* or virinae*))).mp.	Free text terms for COVID-19 (adapted from ²)
3	1 or 2	Combine articles identified by rows 1 or 2
4	Vaccines/ or COVID-19 Vaccines/ or immunization/ or immunization schedule/ or vaccination/	Controlled vocabulary terms for vaccine
5	(vaccin* or immunis* or immuniz*).mp.	Free text terms for vaccine
6	4 or 5	Combine articles identified by rows 4 or 5
7	(heterologous or prim* or boost* or mix*).mp.	Free text terms for heterologous schedules
8	3 and 6 and 7	Select articles identified by rows 3, 6, and 7
9	Limit 8 to dt="20200701-20211119"	Limit to studies uploaded from 1 July 2020

Preprints in *medRxiv* were identified using the search strategy given below, implemented on 22 November 2021 with the package *medrxivr* using the programming language R.

Row	Term	Purpose
1	("coronavirus" or "COVID-19" or "SARS-CoV-2")	Free text terms for COVID-19
2	("vaccine" or "vaccines")	Free text terms for vaccine
3	("heterologous" or "mixed" or "mix" or "boost" or "booster" or "boosters")	Free text terms for heterologous schedules
4	1 and 2 and 3	Select articles identified by rows 1, 2, and 3

The search was extended by scanning the reference lists of included articles and by consulting experts in the field. Studies published after the formal searches described above were included, up to a final cut-off of 6 December 2021.

Scope and eligibility criteria

Duplicates were removed, and titles and abstracts were screened to identify articles reporting on the safety, immunogenicity, and/or vaccine effectiveness (VE) of a heterologous COVID-19 vaccine schedule involving a combination of WHO Emergency Use Listing (EUL) COVID-19 vaccines from multiple platforms (e.g. a vectored vaccine followed by an mRNA vaccines). At the time of the search, the list of WHO EUL products included Ad26.COV2.S (Janssen), BIBP (Sinopharm), BNT162b2 (Pfizer/BioNTech), ChAdOx1-S (AstraZeneca), CoronaVac (Sinovac), Covaxin (Bharat), and mRNA-1273 (Moderna). Articles reporting heterologous vaccine outcomes for fewer than 10 non-immunocompromised individuals were excluded. Multiple reports on the same population were combined under a single study ID during data extraction.


Data extraction

Data were extracted on study location, design, size, vaccine schedules, and dosing interval across all included studies. For studies of VE, we extracted data on: start and end dates; duration of follow-up (average and range); variant profile; and adjusted VE estimates, stratified by vaccine schedule and outcome (infection, symptomatic disease, hospitalisation, and/or intensive care unit admission).


For studies reporting on antibody response, we extracted data on: timing of sample collection after the final dose; binding antibody assay endpoint (target and assay); neutralizing antibody assay endpoint (measurement and target); and average binding and neutralizing antibody levels, stratified by vaccine schedule. We used Plot Digitizer³ software to extract average (mean/median) antibody concentrations where these were not reported directly. We prioritised RBD-specific binding antibody concentrations and wild-type-specific neutralizing antibody concentrations where multiple endpoints were reported. Where antibody responses were reported at multiple timepoints, samples obtained 4 weeks after vaccination (or the nearest available timepoint) were selected. Formal analysis of reactogenicity data was beyond the scope of this review, but key trends are summarised in the main text. Cellular immunity endpoints were beyond the scope of this review.

Studies were included in the quantitative synthesis of antibody response rates if they reported post-vaccination antibody response data (binding or neutralizing antibody concentrations) for comparable heterologous and homologous schedules. These were used to calculate the ratio of antibody concentrations between heterologous and homologous vaccine groups, whereby a ratio of >1 indicates higher antibody levels among heterologous vaccine recipients. Given the multiplicity of vaccine products and schedules involved, we did not seek to combine these ratios into pooled estimates. Comparisons were excluded if they involved a different number of doses overall (e.g. Ad26.COV2.S–BNT162b2 vs BNT162b2–BNT162b2–BNT162b2).

Ad26.COV2.S can be given as a one-dose or two-dose primary series. For the purposes of this review, a two-dose heterologous series involving Ad26.COV2.S alongside another COVID-19 vaccine was considered a heterologous primary series.



Supplementary Figure 1. Flow diagram. *Includes studies published after 19 November 2021; † identified via bibliographies and expert recommendation; § includes studies reporting on SARS-CoV-2 infection rates by vaccine group without vaccine effectiveness estimates.



Supplementary Figure 2. Comparative immunogenicity of COVID-19 vaccine schedules involving heterologous versus homologous platforms. Post-vaccination antibody ratios are presented relative to (A) homologous inactivated vaccine schedules, (B) homologous vectored vaccine schedules, and (C) homologous mRNA vaccine schedules. Citation details are provided in the appendix (pp8–13). For studies in which the number of participants differed between binding and neutralizing antibody measurements, we quote the higher number here. Some study arms used as a reference for multiple heterologous schedules). Ab, antibody; AZ, AstraZeneca (ChAdOx1-S); BH, Bharat (Covaxin); CT, clinical trial; INA, inactivated; OBS, observational; SP, Sinopharm (BIBP); SV, Sinovac (CoronaVac); VEC, vectored.

Supplementary Table 1. Evidence of COVID-19 vaccine effectiveness for schedules involving heterologous platforms.

The table below includes studies reporting estimates of VE following heterologous vaccine series involving a combination of WHO EUL COVID-19 vaccine. VE estimates for RNA vaccines (i.e. BNT162b2 and mRNA-1273) were combined where possible. Vaccination groups without a relevant heterologous comparator (e.g. those involving a single dose) were excluded.

Study	Country	Group	Design	Start date	End date	Follow-up interval in days, median (range)	Major variant (% cases) [notes]	Outcome	Schedule (interval before last dose in weeks) ^a	Event rate, n/N (%) or n/person-years (incidence rate) if marked by *	VE (95% CI)
Gram et al. ^{4b}	Denmark	Primary	Cohort	9 Feb 2021	23 Jun 2021	133 (1–135)	Alpha (n.r.)	Infection	AZ-RNA (12)	29/7775 (0.004)*	88 (83–92)
Skowronski et al. ^{5c}	Canada	Primary	Test-negative case-control	30 May 2021	2 Oct 2021	76 (2–231)	Delta (91)	Hospitalisation	AZ-RNA (≥ 3)	2/14 084 (0.01)	99 (98–100)
						AZ-AZ (≥ 3)			17/8077 (0.2)	94 (90–96)	
						RNA-RNA (≥ 3)			178/230 188 (0.1)	98 (97–98)	
						68 (0–250)		Infection	AZ-RNA (≥ 3)	404/14 084 (2.9)	90 (89–91)
						AZ-AZ (≥ 3)			645/8077 (8.0)	71 (69–74)	
						RNA-RNA (≥ 3)			6595/230 188 (2.9)	90 (90–91)	
Nordstrom et al. ^{6d}	Sweden	Primary	Cohort	19 Dec 2020	20 Feb 2021	76 (1–183)	Delta (n.r.)	Symptomatic	AZ-BNT (n.r.)	170/94 569 (0.2)	67 (59–73)
						AZ-MOD (n.r.)			17/16 402 (0.1)	79 (62–88)	
						AZ-AZ (n.r.)			446/430 100 (0.1)	50 (41–58)	
						BNT-BNT (n.r.)			5113/2 065 831 (0.2)	78 (78–79)	
						MOD-MOD (n.r.)			312/248 234 (0.1)	87 (84–88)	
Starfelt et al. ^{7e}	Norway	Primary	Cohort	1 Jan 2021	27 Sep 2021	269 (n.r.)	n.r. [follow-up spans Alpha- and Delta-dominated periods]	Infection	AZ-RNA (n.r.)	702/132 630 (0.5)	61 (58–64)
						AZ-AZ (n.r.)			14/1438 (1.0)	43 (4–67)	
						BNT-BNT (n.r.)			5548/2 494 177 (0.2)	70 (69–71)	
						MOD-MOD (n.r.)			1038/420 588 (0.2)	78 (77–80)	
						Mixed mRNA (n.r.)			428/625 060 (0.1)	85 (83–86)	
Martínez-Baz et al. ^{8f}	Spain	Primary	Cohort of close contacts of positive cases	Apr 2021	Aug 2021	n.r.	n.r. [follow-up spans Alpha- and Delta-dominated periods]	Infection	AZ-BNT (n.r.)	7/119 (3.5)	86 (70–93)
									AZ-AZ (n.r.)	272/1539 (17.7)	54 (48–60)
									BNT-BNT (n.r.)	1070/7972 (13.4)	69 (66–72)
								Symptomatic	AZ-BNT (n.r.)	3/119 (2.5)	91 (71–97)
									AZ-AZ (n.r.)	173/1539 (11.2)	56 (48–63)
									BNT-BNT (n.r.)	645/7972 (8.1)	72 (69–75)
								Hospitalisation	AZ-BNT (n.r.)	0/119 (0.0)	100 (n.r.)
									AZ-AZ (n.r.)	2/1539 (0.1)	95 (79–99)
									BNT-BNT (n.r.)	20/7972 (0.3)	93 (88–96)

Poukka et al. ⁹	Finland	Primary	Cohort of health-care workers	27 Dec 2020	26 Aug 2021	n.r. (14–180)	n.r. [follow-up spans Alpha- and Delta-dominated periods]	Infection (from 14 to 90 days after dose 2)	AZ-RNA (n.r.)	n.r.	80 (82–86)
									AZ-AZ (n.r.)	n.r.	89 (73–95)
									RNA-RNA (n.r.)	n.r.	82 (79–85)
								Infection (from 91 to 180 days after dose 2)	AZ-RNA (n.r.)	n.r.	62 (30–79)
									AZ-AZ (n.r.)	n.r.	63 (-166–95)
									RNA-RNA (n.r.)	n.r.	62 (55–68)
									AZ-BNT (12)	10/2512 (0.4)	n. r.
									BNT-BNT (4)	81/10 609 (0.8)	n. r.
Prieto-Alhambra et al. ^{11g}	Spain	Primary	Cohort	1 Jun 2021	13 Oct 2021	n.r.	Delta (n.r.)	Infection	AZ-RNA (n.r.)	238/14 325 (1.7)	n. r.
									AZ-AZ (n.r.)	389/14 325 (2.7)	n. r.
Andrews et al. ^{12h}	England	Boost	Test-negative case-control	13 Sep 2021	29 Oct 2021	n.r.	n.r. [follow-up spans Delta-dominated period]	Symptomatic	AZ-AZ-BNT (≥ 24)	138/1266 (0.11)	93 (92–94)
									BNT-BNT-BNT (≥ 24)	518/5905 (0.09)	94 (93–95)
Preliminary data ¹³	Bahrain	Boost	n.r.	1 May 2021	11 Sep 2021	n.r.	n.r.	Symptomatic	SP-SP-BNT (n.r.)	175/265 296 (0.07)	n.r.
									SP-SP-SP (n.r.)	64/29 054 (0.22)	n.r.
Araos et al. ¹⁴ⁱ	Chile	Primary	Cohort	n.r.	n.r.	n.r.	Infection	AZ-BNT (n.r.)	227/31 491 (0.007)*	80 (77–82)	
								AZ-AZ (n.r.)	200/16 752 (0.012)*	68 (63–72)	
								BNT-BNT (n.r.)	8651/625 499 (0.014)*	82 (81–82)	
							Symptomatic	AZ-BNT (n.r.)	144/32 168 (0.004)*	83 (80–86)	
								AZ-AZ (n.r.)	133/17 101 (0.008)*	73 (68–77)	
								BNT-BNT (n.r.)	5628/633 358 (0.009)*	85 (85–86)	
							Hospitalisation	AZ-BNT (n.r.)	1/33 847 (0.00003)*	99 (93–100)	
								AZ-AZ (n.r.)	18/17 928 (0.001)*	88 (82–91)	
								BNT-BNT (n.r.)	337/655 399 (0.001)*	95 (94–195)	
							ICU admission	AZ-BNT (n.r.)	1/33 910 (0.00003)*	96 (78–99)	
								AZ-AZ (n.r.)	3/18 051 (0.0002)*	95 (84–98)	
								BNT-BNT (n.r.)	82/656 614 (0.0001)*	96 (95–97)	
							Infection	SV-SV-AZ (n.r.)	428/153 954 (0.003)*	90 (89–91)	
								SV-SV-BNT (n.r.)	82/33 025 (0.002)*	93 (91–94)	
								SV-SV-SV (n.r.)	123/13 490 (0.009)*	68 (61–73)	
Boost											

							Symptomatic	SV-SV-AZ (n.r.)	249/155 226 (0.002)*	93 (92–94)
							SV-SV-BNT (n.r.)	51/33 393 (0.002)*	95 (93–96)	
							SV-SV-SV (n.r.)	97/13 611 (0.007)*	71 (64–76)	
Hospitalisation							SV-SV-AZ (n.r.)	53/158 216 (0.0003)*	96 (95–97)	
							SV-SV-BNT (n.r.)	24/34 383 (0.001)*	89 (84–93)	
							SV-SV-SV (n.r.)	34/13 908 (0.002)*	75 (65–82)	
ICU admission							SV-SV-AZ (n.r.)	8/158 522 (0.0001)*	98 (96–99)	
							SV-SV-BNT (n.r.)	6/34 499 (0.0002)*	90 (78–95)	
							SV-SV-SV (n.r.)	9/13 977 (0.001)*	79 (59–89)	

AZ: AstraZeneca (ChAdOx1-S); BNT: Pfizer-BioNTech (BNT162b2); CI: confidence interval; d: days; ICU: intensive care unit; MOD: Moderna (mRNA-1273); n.r.: not recorded; RNA: mRNA vaccines (BNT162b2 or mRNA-1273); SP: Sinopharm (BIBP) SV: Sinovac (CoronaVac); VE: vaccine effectiveness.

^a Mean/median interval rounded to nearest week, or range if average interval not specified.

^b VE estimate were adjusted for age, sex, heritage, hospital admission, and comorbidity.

^c Median follow-up of 58 days for controls (range 0–265). Interval between doses varied from 3 to ≥16 weeks, with >70% in the range of 7–11 weeks. Data for British Columbia are displayed. Similar findings were reported for Quebec. Over 99% of heterologous vaccine recipients received ChAdOx1-S first. VE estimates were adjusted for age, sex, epidemiological week, and region. Combined rather than vaccine-specific VE are reported for mRNA vaccines.

^d VE estimates were adjusted for age, sex, baseline vaccination date, home-maker service, place of birth, education, and diagnoses at baseline.

^e VE estimates were adjusted for age, sex, country of birth, and crowded living conditions.

^f VE estimates were adjusted for age group, sex, chronic conditions, contact setting, month, and vaccination status of index case.

^g Vaccine groups were matched by age, sex, region, and date of second dose.

^h Population comprised adults over 50 years of age. Absolute VE relative to unvaccinated individuals is reported. Relative VE for AZ-AZ-BNT vs AZ-AZ (140+ days since second dose) was 87% (95% CI: 85–89%); relative VE for BNT-BNT-BNT vs BNT-BNT (140+ days since second dose) was 84% (95% CI: 82–86%). VE estimates were adjusted for age, sex, deprivation, ethnic group, care home residence status, region, calendar week of onset, health and social care worker status, clinical risk group, extreme clinical vulnerability, immunosuppression status, and prior positive testing.

ⁱ VE estimates were adjusted for age and sex, among others (full list not specified in available data).

Supplementary Table 2. Relative binding and neutralizing antibody concentrations for heterologous versus homologous vaccine schedules involving a combination of WHO EUL COVID-19 vaccines. Data are displayed for (A) inactivated vaccines; (B) vectored vaccines; and (C) mRNA vaccines.

Comparisons were included if antibody concentrations were reported for comparable heterologous and homologous schedules. Comparisons were excluded if they involved a different number of doses overall (e.g. JNJ-MOD vs MOD-MOD-MOD). Where antibody responses were reported at multiple timepoints, samples obtained 4 weeks after vaccination (or the nearest available timepoint) were selected. RBD-specific binding antibody concentrations and wild-type-specific neutralizing antibody concentrations were prioritised where multiple endpoints were reported. Some study arms are included in multiple comparisons (e.g. one homologous group used as a reference for multiple heterologous schedules).

(A) WHO EUL inactivated vaccines: heterologous vs homologous schedules

Study	Country	Group	Design	Heterologous schedule (interval before last dose in weeks) ^a	Homologous schedule (interval before last dose in weeks) ^a	Time of sampling after last dose (weeks) ^a	Ig endpoint (assay)	GMC (95% CI) or median concentration (IQR) (marked as *) [N]		Ig ratio	NAb endpoint (target)	GMC (95% CI) or median concentration (IQR) (marked as *) [N]		NAb ratio
								Heterologous	Homologous			Heterologous	Homologous	
Kant et al. ¹⁵	India	Primary	OBS	AZ-BH (6)	BH-BH (4)	≥2	RBD-IgG (n.r.)	1866 (1003–3472) [18]	710 (461–1092) [40]	2.6	PRNT50 (B.1)	539.4 (263.9–1103) [18]	156.6 (105.2–233.1) [40]	3.4
Mahasirimongkol et al. ¹⁶	Thailand	Primary	OBS	SV-AZ (3.5)	SV-SV (3.5)	4	RBD-IgG (Abbott)	639 (63–726) [137]	108.2 (77–152) [32]	5.9	n.r.	n.r.	n.r.	n.r.
Wanlapakorn et al. (i) ¹⁷	Thailand	Primary	OBS	SV-AZ (4)	SV-SV (4)	4–5	RBD-Ig (Roche)	573.4 (417.2–788.0) [44]	99.4 (77.5–127.3) [90]	5.8	% inhibition (sVNT pseudo-virus)	95.0*§ (86.8–97.8) [44]	48.8*§ (28.9–68.8) [90]	—
Wanlapakorn et al. (ii) ¹⁷	Thailand	Primary	OBS	AZ-SV (10)	SV-SV (4)	4	RBD-Ig (Roche)	375.8 (304.9–463.3) [46]	99.4 (77.5–127.3) [90]	3.8	% inhibition (sVNT pseudo-virus)	50.0*§ (30.3–69.0) [40]	48.8*§ (28.9–68.8) [90]	—
Yorsaeng et al. ¹⁸	Thailand	Primary	OBS	SV-AZ (4)	SV-SV (3)	4	S-Ig (Roche)	797.2 (598.7–1062) [54]	96.4 (76.1–122.1) [80]	8.3	n.r.	n.r.	n.r.	n.r.
Angkasekwinai et al. (i) ^{19b}	Thailand	Boost	OBS	SV-SV-AZ (8–12)	SV-SV-SP (8–12)	2	S-IgG (Abbott)	1358 (1142–5910) [65]	154.6 (92.1–259.5) [14]	8.8	PRNT50 (Delta)	271.2 (222.5–330.5) [65]	61.3 (35.1–107.0) [14]	4.4
Wanlapakorn et al. (iii) ²⁰	Thailand	Primary	OBS	SV-BNT (3)	SV-SV (3)	4	RBD-Ig (Roche)	1042 (828.6–1311) [66]	97.9 (82.6–116.1) [170]	10.6	% inhibition (sVNT pseudo-virus)	95.5*§ (93.0–96.6) [66]	66.6*§ (48.9–79.4) [170]	—
Angkasekwinai et al. (ii) ^{19b}	Thailand	Boost	OBS	SV-SV-BNT (8–12)	SV-SV-SP (8–12)	2	S-IgG (Abbott)	5152 (1142–1615) [50]	154.6 (92.1–259.5) [14]	33.3	PRNT50 (Delta)	411.1 (311.7–542.2) [30]	61.3 (35.1–107.0) [14]	6.7
Keskin et al. ²¹	Turkey	Boost	OBS	SV-SV-BNT (24)	SV-SV-SV (24)	4	S-IgG (Abbott)	25 538 (18 502)* [27]	947.3 (1405.3)* [18]	27.0	n.r.	n.r.	n.r.	n.r.
Pun Mok et al. ²²	China	Boost	CT	SV-SV-BNT (>4)	SV-SV-SV (>4)	4	RBD-Ig (in-house)	n.r.	n.r.	n.r.	% inhibition (sVNT)	96.8§ (n.r.) [40]	57.8§ (n.r.) [40]	—

										pseudo-virus)				
Preliminary data ^{13c}	Bahrain	Boost	CT	SP-SP-BNT (24)	SP-SP-SP (24)	8	S-Ig (n.r.)	14 849 (n.r.) [153]	1187.3 (n.r.) [152]	12.5	% inhibition (sVNT pseudo-virus)	96.9§ (n.r.) [153]	63.4§ (n.r.) [152]	—

(B) WHO EUL vectored vaccines: heterologous vs homologous schedules

Study	Country	Group	Design	Heterologous schedule (interval before last dose in weeks) ^a	Homologous schedule (interval before last dose in weeks) ^a	Time of sampling after last dose (weeks) ^a	Ig endpoint (assay)	GMC (95% CI) or median concentration (IQR) (marked as *) [N]		Ig ratio	NAb endpoint (target)	GMC (95% CI) or median concentration (IQR) (marked as *) [N]		NAb ratio
								Heterologous	Homologous			Heterologous	Homologous	
Kant et al. ¹⁵	India	Primary	OBS	AZ-BH (6)	AZ-AZ (6)	≥2	RBD-IgG (n.r.)	1866 (1003–3472) [18]	2260 (1881–2716) [40]	0.8	PRNT50 (B.1)	539.4 (263.9–1103) [18]	162 (76.74–342) [40]	3.3
Mahasirimongkol et al. ¹⁶	Thailand	Primary	OBS	SV-AZ (3.5)	AZ-AZ (8–12)	4	RBD-IgG (Abbott)	639 (63–726) [137]	211.1 (162–249) [47]	3.0	n.r.	n.r.	n.r.	n.r.
Wanlapakorn et al. (i) ¹⁷	Thailand	Primary	OBS	SV-AZ (3.5)	AZ-AZ (10)	4–5	RBD-Ig (Roche)	573.4 (417.2–788.0) [44]	933.7 (775.4–1124.0) [89]	0.6	% inhibition (sVNT pseudo-virus)	95.0*§ (86.8–97.8) [44]	77.2*§ (57.0–89.7) [90]	—
Wanlapakorn et al. (ii) ¹⁷	Thailand	Primary	OBS	AZ-SV (10)	AZ-AZ (10)	4	S-Ig (Roche)	375.8 (304.9–463.3) [46]	933.7 (775.4–1124.0) [89]	0.4	% inhibition (sVNT pseudo-virus)	50.0*§ (30.3–69.0) [40]	77.2*§ (57.0–89.7) [90]	—
Yorsaeng et al. ¹⁸	Thailand	Primary	OBS	SV-AZ (4)	AZ-AZ (10)	4	S-Ig (Roche)	797.2 (598.7–1062) [54]	818.1 (662.5–1010) [80]	1	n.r.	n.r.	n.r.	n.r.
Angkasekwinai et al. (i) ^{19b}	Thailand	Boost	OBS	AZ-AZ-SP (8–12)	AZ-AZ-AZ (8–12)	2	S-IgG (Abbott)	128.1 (93.5–175.4) [23]	246.4 (188.6–304.2) [50]	0.5	PRNT50 (Delta)	49.0 (37.6–64.1) [22]	69.1 (50.1–95.1) [30]	0.7
Atmar et al. (i) ^{23d}	USA	Boost	CT	JNJ-MOD (14)	JNJ-JNJ (18)	2	S-Ig (MSD)	3203.1 (2499.5–4104.9) [53]	326.0 (235.8–450.7) [50]	9.8	IU50/ml (D614G pseudo-virus)	676.1 (517.5–883.3) [53]	31.4 (22.3–44.3) [50]	21.5
Atmar et al. (ii) ^{23d}	USA	Boost	CT	JNJ-BNT (20)	JNJ-JNJ (18)	2	S-Ig (MSD)	2549.5 (2038.1–3189.3) [53]	326.0 (235.8–450.7) [50]	7.8	IU50/ml (D614G pseudo-virus)	341.3 (239.6–486.3) [53]	31.4 (22.3–44.3) [50]	10.9
Barros-Martins et al. ²⁴	Germany	Primary	OBS	AZ-BNT (10)	AZ-AZ (10)	2	RBD-IgG (Euroimmun)	625.7 (n.r.) [55]	160.9 (n.r.) [32]	3.9	Reciprocal titre (sVNT pseudo-virus)	4432*† (n.r.) [54]	529*† (n.r.) [31]	8.4

Benning et al. ²⁵	Germany	Primary	OBS	AZ-BNT (12)	AZ-AZ (12)	3	S1-IgG (Siemens)	116.2* (61.8–170) [35]	13.1* (7.0–29.0) [17]	8.9	% inhibition (sVNT pseudovirus)	96.8*§ (96.7–96.9) [35]	93.5*§ (88.6–96.7) [17]	n.r.
Brehm et al. ²⁶	Germany	Primary	OBS	AZ-RNA (12)	AZ-AZ (12)	1	RBD-Ig (Roche)	9450* (n.r.) [106]	1069* (n.r.) [25]	8.8	n.r.	n.r.	n.r.	n.r.
Dimeglio et al. ^{27d}	France	Primary	OBS	AZ-BNT (12)	AZ-AZ (12)	4	n.r.	n.r.	n.r.	n.r.	n.r. (n.r.)	255*† (n.r.) [22]	50*† (n.r.) [22]	5.1
Havervall et al. ²⁸	Sweden	Primary	OBS	AZ-BNT (13)	AZ-AZ (12)	2–3	n.r.	n.r.	n.r.	n.r.	AU/ml (WT)	35*† (n.r.) [116]	25*† (n.r.) [82]	1.4
Hillus et al. ²⁹	Germany	Primary	OBS	AZ-BNT (10)	AZ-AZ (12)	3	RBD-IgG S/Co (SeraSpot)	5.6*§ (5.1–6.1) [104]	4.9*§ (4.3–5.6) [38]	—	% inhibition (sVNT pseudovirus)	97.1*§ (96.9–97.3) [94]	92.4*§ (86.4–96.4) [36]	—
Liu et al. (i) ³⁰	United Kingdom	Primary	CT	AZ-BNT (4)	AZ-AZ (4)	4	S-IgG (Nexelis)	12 906 (11 404–14 604) [104]	1392 (1188–1630) [104]	9.3	NT50 (pseudovirus)	515 (430–617) [101]	61 (50–73) [101]	8.4
Liu et al. (ii) ³⁰	United Kingdom	Primary	CT	BNT-AZ (4)	AZ-AZ (4)	4	S-IgG (Nexelis)	7133 (6415–7932) [109]	1392 (1188–1630) [104]	5.1	NT50 (pseudovirus)	383 (317–463) [104]	61 (50–73) [101]	6.3
Normark et al. ³¹	Sweden	Primary	OBS	AZ-MOD (11)	AZ-AZ (11)	4	S-Ig (n.r.)	104 083 (n.r.) [51]	7381 (n.r.) [37]	14.1	In-house Vero NT (Alpha)	1259† (n.r.) [20]	88† (n.r.) [34]	14.3
Sablerolles et al. (i) ³²	Netherlands	Primary	CT	JNJ-MOD (12)	JNJ-JNJ (12)	4	S-IgG (Liaison)	4180*† (n.r.) [122]	470*† (n.r.) [106]	8.9	PRNT50 (D614G)	1450*† (n.r.) [54]	326*† (n.r.) [50]	4.4
Sablerolles et al. (ii) ³²	Netherlands	Primary	CT	JNJ-BNT (12)	JNJ-JNJ (12)	4	S-IgG (Liaison)	2625*† (n.r.) [111]	470*† (n.r.) [106]	5.6	PRNT50 (D614G)	1450*† (n.r.) [53]	326*† (n.r.) [106]	4.4
Schmidt et al. ³³	Germany	Primary	OBS	AZ-RNA (11)	AZ-AZ (11)	2	RBD-IgG (Euroimmun)	3630* (3721) [96]	404* (510) [55]	9	% inhibition (sVNT pseudovirus)	100*†§ (100–100) [96]	84*†§ (61–96) [55]	—
Tenbusch et al. ³⁴	Germany	Primary	OBS	AZ-BNT (9)	AZ-AZ (9)	2	n.r.	n.r.	n.r.	n.r.	AU/ml (sVNT pseudovirus)	3377* (n.r.) [482]	106* (n.r.) [66]	31.9
Thurm et al. ³⁵	Germany	Primary	OBS	AZ-RNA (11)	AZ-AZ (11)	4	S1-IgG (Thermo-Fisher)	1640 (1227–2053) [42]	154.4 (103.5–205.4) [38]	10.6	% inhibition (WT)	99.1§ (98.7–99.6) [42]	72.0§ (64.7–79.4) [38]	—
Angkasek-winai et al. (ii) ^{19b}	Thailand	Boost	OBS	AZ-AZ-BNT (8–12)	AZ-AZ-AZ (8–12)	2	S-IgG (Abbott)	2364 (2006–2786) [50]	246.4 (188.6–304.2) [50]	9.6	PRNT50 (Delta)	470.1 (395.5–558.9) [30]	69.1 (50.1–95.1) [30]	6.8

Munro et al (i) ^{36f}	UK	Boost	CT	AZ-AZ-BNT (11)	AZ-AZ-AZ (11)	4	S-IgG (Nexelis)	20 517 (17 718– 23 757) [93]	2457 (2058–2933) [99]	8.4	NT50 (WT pseudo- virus)	1621 (1314–1998) [93]	193 (161–231) [98]	8.4
Munro et al (ii) ^{36f}	UK	Boost	CT	AZ-AZ-MOD (11)	AZ-AZ-AZ (11)	4	S-IgG (Nexelis)	31 111 (26 363– 36 714) [97]	2457 (2058–2933) [99]	12.7	NT50 (WT pseudo- virus)	2368 (2054–2730) [97]	193 (161–231) [98]	12.3

(C) WHO EUL RNA vaccines: heterologous vs homologous schedules

Study	Country	Group	Design	Heterologous schedule (interval before last dose in weeks) ^a	Homologous schedule (interval before last dose in weeks) ^a	Time of sampling after last dose (weeks) ^a	Ig endpoint (assay)	GMC (95% CI) or median concentration (IQR) (marked as *) [N]		Ig ratio	NAb endpoint (target)	GMC (95% CI) or median concentration (IQR) (marked as *) [N]		NAb ratio
								Heterologous	Homologous			Heterologous	Homologous	
Wanlapakorn et al. ²⁰	Thailand	Primary	OBS	SV-BNT (3)	BNT-BNT (3)	4–5	RBD-IgG (Roche)	1042 (828.6–1311) [66]	1963 (1378–2798) [19]	0.5	% inhibition (sVNT pseudo-virus)	95.5*§ (93.0–96.6) [66]	97.4*§ (96.3–97.7) [19]	–
Barros-Martins et al. ²⁴	Germany	Primary	OBS	AZ-BNT (10)	BNT-BNT (3)	2–4	RBD-IgG (Euroimmun)	625.7 (n.r.) [55]	574.1 (n.r.) [46]	1.1	Reciprocal titre (sVNT pseudo-virus)	4432*† (n.r.) [54]	6568*† (n.r.) [30]	0.7
Benning et al. ²⁵	Germany	Primary	OBS	AZ-BNT (12)	BNT-BNT (3)	3	S1-IgG (Siemens)	116.2* (61.8–170) [35]	145.5* (100.0–291.1) [82]	0.8	% inhibition (sVNT pseudo-virus)	96.8*§ (96.7–96.9) [35]	97.0*§ (96.1–98.0) [82]	–
Brehm et al. ²⁶	Germany	Primary	OBS	AZ-RNA (12)	RNA-RNA (6)	1–15	RBD-IgG (Roche)	9450* (n.r.) [106]	1388* (n.r.) [261]	6.8	n.r.	n.r.	n.r.	n.r.
Dimeglio et al. ^{27c}	France	Primary	OBS	AZ-BNT (12)	BNT-BNT (4)	4	n.r.	n.r.	n.r.	n.r.	n.r.	255*† (n.r.) [22]	168*† (n.r.) [22]	1.5
Glockner et al. ³⁷	Germany	Primary	OBS	AZ-RNA (12)	RNA-RNA (3)	4–5	S-IgG (Liaison)	1640 (1227–2053) [42]	1714 (1404–2025) [41]	1.0	n.r.	n.r.	n.r.	n.r.
Groß et al. ³⁸	Germany	Primary	OBS	AZ-BNT (8)	BNT-BNT (n.r.)	2	S-IgG (Roche)	8815* (n.r.) [26]	1086* (n.r.) [15]	8.1	NT50 (Alpha pseudo-virus)	2744* (n.r.) [25]	709* (n.r.) [14]	3.9
Havervall et al. ²⁸	Sweden	Primary	OBS	AZ-BNT (13)	BNT-BNT (3)	2–8	n.r.	n.r.	n.r.	n.r.	AU/ml (WT)	35*† (n.r.) [116]	30*† (n.r.) [101]	1.2
Hillus et al. ²⁹	Germany	Primary	OBS	AZ-BNT (10)	BNT-BNT (3)	3–4	RBD-IgG S/Co (SeraSpot)	5.6*§ (5.1–6.1) [104]	5.4*§ (4.8–5.9) [174]	–	% inhibition (sVNT pseudo-virus)	97.1*§ (96.9–97.3) [94]	96.6*§ (95.5–97.2) [101]	–

Liu et al. (i) ³⁰	United Kingdom	Primary	CT	AZ-BNT (4)	BNT-BNT (4)	4	S-IgG (Nexelis)	12 906 (11 404–14 604) [104]	14 080 (12 491–15 871) [109]	0.9	NT50 (pseudo-virus)	515 (430–617) [101]	574 (475–694) [102]	0.9
Liu et al. (ii) ³⁰	United Kingdom	Primary	CT	BNT-AZ (4)	BNT-BNT (4)	4	S-IgG (Nexelis)	7133 (6415–7932) [109]	14 080 (12 491–15 871) [109]	0.5	NT50 (pseudo-virus)	383 (317–463) [104]	574 (475–694) [102]	0.7
Pozzetto et al. ¹⁰	France	Primary	OBS	AZ-RNA (12)	BNT-BNT (4)	4	RBD-IgG (Liaison)	1068*† (814–1682) [31]	944*† (608–1394) [29]	1.0	% inhibition (sVNT pseudo-virus)	99*§ (89–100) [31]	62*§ (34–93) [29]	—
Schmidt et al. ³³	Germany	Primary	OBS	AZ-RNA (11)	RNA-RNA (5)	2	RBD-IgG (Euroimmun)	3630* (3721) [96]	4932 (4239) [62]	0.7	% inhibition (sVNT pseudo-virus)	100*†§ (100–100) [96]	100*†§ (100–100) [62]	—
Tenbusch et al. ³⁴	Germany	Primary	OBS	AZ-BNT (9)	BNT-BNT (3)	2	n.r.	n.r.	n.r.	n.r.	AU/ml (sVNT pseudo-virus)	3377* (n.r.) [482]	1789* (n.r.) [537]	1.9
Thurm et al. ³⁵	Germany	Primary	OBS	AZ-RNA (11)	RNA-RNA (5)	4	S1-IgG (Thermo-Fisher)	2411 (1689–3441) [21]	1755 (1219–2527) [22]	1.4	% inhibition (WT)	99.1*§ (98.7–99.6) [42]	99.0*§ (98.3–99.6) [38]	—
Vallée et al. ³⁹	France	Primary	OBS	AZ-BNT (12)	BNT-BNT (4)	5–6	S-IgG (Abbott)	7268.6 (6501.3–8128.3) [130]	10 734.9 (9141.1–12 589.3) [67]	0.7	n.r.	n.r.	n.r.	n.r.
Atmar et al. (i) ^{23d}	USA	Boost	CT	MOD-MOD-JNJ (19)	MOD-MOD-MOD (16)	2	S-Ig (MSD)	3029.4 (2433.2–3771.7) [49]	6799.8 (5771.8–8010.9) [51]	0.4	IU50/ml (D614G pseudo-virus)	382.1 (290.5–502.5) [49]	901.8 (727.5–1117.8) [51]	0.4
Atmar et al. (ii) ^{23d}	USA	Boost	CT	BNT-BNT-JNJ (21)	BNT-BNT-BNT (24)	2	S-Ig (MSD)	1904.7 (1497.8–2422.2) [51]	3409.1 (2760.7–4209.8) [50]	0.3	IU50/ml (D614G pseudo-virus)	216.4 (157.8–296.9) [51]	446.7 (340.3–586.3) [50]	0.5
Munro et al (i) ^{36f}	UK	Boost	CT	BNT-BNT-AZ (16)	BNT-BNT-BNT (14)	4	S-IgG (Nexelis)	13 424 (11 702–15 399) [97]	27 242 (24 148–30 731) [96]	0.5	NT50 (WT pseudo-virus)	950 (802–1126) [98]	1789 (1520–2107) [95]	0.5
Munro et al (ii) ^{36f}	UK	Boost	CT	BNT-BNT-JNJ (15)	BNT-BNT-BNT (14)	4	S-IgG (Nexelis)	17 079 (14 488–20 133) [87]	27 242 (24 148–30 731) [96]	0.6	NT50 (WT pseudo-virus)	1441 (1188–1749) [75]	1789 (1520–2107) [95]	0.8

† approximate values extracted using Plot Digitizer software; § excluded from summary plot as metric is not a titre or concentration and is therefore not comparable to other ratios.

AU: arbitrary units; AZ: AstraZeneca (ChAdOx1-S); BH: Bharat (Covaxin); BNT: Pfizer-BioNTech (BNT162b2); CI: confidence interval; CT: clinical trial (randomized or non-randomized); EUL: Emergency Use Listing (WHO); GMC: geometric mean concentration; Ig: binding antibody; IQR: interquartile range; IU: international units; JNJ: Janssen (Ad26.COV2.S); MOD: Moderna (mRNA-1273); N: number; NAb: neutralizing antibody; NT: neutralization test; NT50: 50% neutralizing antibody titre; OBS: observational study; PRNT: plaque reduction neutralization test; RBD: receptor binding domain; RNA: mRNA vaccines (BNT162b2 or mRNA-1273); SP: Sinopharm (BIBP); SV: Sinovac (CoronaVac); sVNT: surrogate virus neutralization test; WT: wild-type.

Vaccine platform colour coding: green = inactivated; blue = mRNA; orange = vectored. The colour represents the heterologous component that differentiates the schedule from the homologous schedule being used as a reference.

^a Average interval rounded to nearest week, or range if average interval not specified.

^b The administration of SP to individuals who had previously received two doses of SV was considered a homologous boost for the purposes of this comparison. Separate groups received BNT doses at 30 µg (full dose) and 15 µg (fractional dose); the 30 µg recipients were included here, reflecting the formulation in the WHO EUL.

^c Shared with SAGE on 5 October 2021.

^d Comparisons involving different numbers of doses overall were excluded (e.g. JNJ-BNT vs BNT-BNT-BNT).

^e Data for individuals aged >55 years (as opposed to <55 years) included given the presence of homologous RNA and homologous vectored comparators.

^f Trial involved 18 study sites that were split into three groups, with multiple EUL and non-EUL COVID-19 vaccine products per group. Comparisons involving non-EUL vaccine products or fractional doses of EUL products were excluded. Some comparisons involved participants from separate study groups.

References

1. WHO. Interim recommendations for heterologous COVID-19 vaccine schedules (<https://www.who.int/publications/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-heterologous-schedules>, accessed 16 December 2021).
2. Interim process and methods for developing rapid guidelines on COVID-19. National Institute for Health and Care Excellence; 2020 (<https://www.nice.org.uk/process/pmg35/chapter/appendix-search-strategy-for-medline-ovid-platform>, accessed 1 October 2021).
3. Plot Digitizer 2.6.2 (<http://plotdigitizer.sourceforge.net>, accessed 24 May 2013).
4. Gram MA, Nielsen J, Schelde AB, et al. Vaccine effectiveness when combining the ChAdOx1 vaccine as the first dose with an mRNA COVID-19 vaccine as the second dose. *medRxiv* 2021: 2021.07.26.21261130.
5. Skowronski DM, Setayeshgar S, Febriani Y, et al. Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. *medRxiv* 2021: 2021.10.26.21265397.
6. Nordstrom P, Ballin M, Nordstrom A. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study. *Lancet Reg Health Eur* 2021: 100249.
7. Starrfelt J, Buanes EA, Juvet LK, et al. Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, January – September 2021. *medRxiv* 2021: 2021.11.12.21266222.
8. Martinez-Baz I, Trobajo-Sanmartin C, Miqueleiz A, et al. Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. *Euro Surveill* 2021; **26**(39).
9. Poukka E, Baum U, Palmu AA, et al. Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021. *medRxiv* 2021: 2021.11.03.21265791.
10. Pozzetto B, Legros V, Djebali S, et al. Immunogenicity and efficacy of heterologous ChAdOx1/BNT162b2 vaccination. *Nature* 2021.
11. Prieto-Alhambra D, Hermosilla E, Coma E, et al. Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2: a cohort analysis. *Research Square* 2021: 10.21203/rs.3.rs-1074858/v1.
12. Andrews N, Stowe J, Kirsebom F, Gower C, Ramsay M, Bernal JL. Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against covid-19 related symptoms in England: test negative case-control study. *medRxiv* 2021: 2021.11.15.21266341.
13. SAGE. Strategic Advisory Group of Experts on Immunization, 4-8 October 2021, session 4.5 (https://terrance.who.int/mediacentre/data/sage/SAGE_Slidedeck_Oct2021.pdf, accessed 29 November 2021).
14. Araos R, Jara A. Covid-19 vaccine effectiveness assessment in Chile, 25 October 2021 (https://cdn.who.int/media/docs/default-source/blue-print/chile_rafael-araos_who-vr-call_25oct2021.pdf?sfvrsn=7a7ca72a_7, accessed 29 November 2021).
15. Kant R, Dwivedi G, Zaman K, et al. Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin. *J Travel Med* 2021; 10.1093/jtm/taab166.
16. Mahasirimongkol S, Khunphon A, Kwangsukstid O, et al. Immunogenicity and adverse events of priming with inactivated whole SARS-CoV-2 vaccine (CoronaVac) followed by boosting the ChAdOx1 nCoV-19 vaccine. *medRxiv* 2021: 2021.11.05.21264700.
17. Wanlapakorn N, Suntronwong N, Phowatthanasathian H, et al. Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults. *medRxiv* 2021: 2021.11.04.21265908.
18. Yorsaeng R, Vichaiwattana P, Klinfueng S, et al. Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria). *medRxiv* 2021: 2021.09.01.21262955.
19. Angkasekwainai N, Niyomnaitham S, Sewatanon J, et al. The immunogenicity and safety of different COVID-19 booster vaccination following CoronaVac or ChAdOx1 nCoV-19 primary series. *medRxiv* 2021: 2021.11.29.21266947.
20. Wanlapakorn N, Yorsaeng R, Phowatthanasathian H, et al. Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine. *medRxiv* 2021: 2021.11.20.21266644.
21. Keskin AU, Bolukcu S, Ciragil P, Topkaya AE. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen. *J Med Virol* 2021: 10.1002/jmv.27350.
22. Pun Mok CK, Cheng SMS, Chen C, et al. A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac. *medRxiv* 2021: 2021.11.02.21265843.
23. Atmar RL, Lyke KE, Deming ME, et al. Heterologous SARS-CoV-2 booster vaccinations – preliminary report. *medRxiv* 2021: 2021.10.10.21264827.
24. Barros-Martins J, Hammerschmidt SI, Cossmann A, et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. *Nat Med* 2021; **27**(9): 1525-9.
25. Benning L, Tollner M, Hidmark A, et al. Heterologous ChAdOx1 nCoV-19/BNT162b2 prime-boost vaccination induces strong humoral responses among health care workers. 2021; **9**(8):857.
26. Brehm TT, Thompson M, Ullrich F, et al. Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic. *Int J of Hyg Environ Health* 2021; **238**: 113851.
27. Dimeglio C, Herin F, Da-Silva I, et al. Heterologous ChAdOx1-S/BNT162b2 vaccination: neutralizing antibody response to SARS-CoV-2. *Clin Infect Dis* 2021: 10.1093/cid/ciab705.

28. Havervall S, Marking U, Gordon M, et al. Neutralization of VOCs including Delta one year post COVID-19 or vaccine. *medRxiv* 2021; 2021.08.12.21261951.
29. Hillus D, Schwarz T, Tober-Lau P, et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. *Lancet Respir Med* 2021; **9**:1255-65.
30. Liu X, Shaw RH, Stuart ASV, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. *Lancet* 2021; **398**(10303): 856-69.
31. Normark J, Vikström L, Gwon Y-D, et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination. *N Eng J Med* 2021; **385**: 1049-51.
32. Sablerolles RSG, Rietdijk WJR, Goorhuis A, et al. Immunogenicity and reactogenicity of booster vaccinations after Ad26.COV2.S priming. *medRxiv* 2021; 2021.10.18.21264979.
33. Schmidt T, Klemis V, Schub D, et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. *Nat Med* 2021; **27**(9): 1530-5.
34. Tenbusch M, Schumacher S, Vogel E, et al. Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. *Lancet Infect Dis* 2021; **21**(9): 1212-3.
35. Thurm C, Reinhold A, Borucki K, et al. Anti-SARS-CoV-2 vaccination does not induce the formation of autoantibodies but provides humoral immunity following heterologous and homologous vaccination regimens: Results from a clinical and prospective study within professionals of a German University Hospital. *medRxiv* 2021; 2021.11.01.21265737.
36. Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. *Lancet* 2021; 10.1016/S0140-6736(21)02717-3.
37. Glockner S, Hornung F, Baier M, et al. Robust Neutralizing antibody levels detected after either SARS-CoV-2 vaccination or one year after infection. *Viruses* 2021; **13**(10): 2003.
38. Groß R, Zanoni M, Seidel A, et al. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity. *medRxiv* 2021; 2021.05.30.21257971.
39. Vallee A, Vasse M, Mazaux L, et al. An immunogenicity report for the comparison between heterologous and homologous prime-boost schedules with ChAdOx1-S and BNT162b2 vaccines. *J Clin Med* 2021; **10**(17): 3817.